<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03253926</url>
  </required_header>
  <id_info>
    <org_study_id>7475</org_study_id>
    <nct_id>NCT03253926</nct_id>
  </id_info>
  <brief_title>Effect of Lorcaserin on Cannabis Withdrawal and Self-administration</brief_title>
  <official_title>Effect of Lorcaserin on Cannabis Withdrawal and Self-administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators are interested in testing how lorcaserin influences the
      effects of cannabis in a human laboratory model of cannabis use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to improve treatment outcome for cannabis use disorder (CUD), the investigators have
      developed a laboratory model to investigate the effects of potential treatment medications on
      cannabis withdrawal and on the subjective and reinforcing effects of cannabis in non
      treatment-seeking cannabis smokers. In this study, the investigators are interested in
      testing how lorcaserin influences the effects of cannabis in a human laboratory model of
      cannabis use.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 5, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cannabis self-administration</measure>
    <time_frame>14 days</time_frame>
    <description>Number of cannabis cigarettes participant chooses to smoke.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Cannabis Use</condition>
  <arm_group>
    <arm_group_label>Lorcaserin + Marijuana</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Marijuana</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorcaserin</intervention_name>
    <description>Lorcaserin 10mg BID</description>
    <arm_group_label>Lorcaserin + Marijuana</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule BID</description>
    <arm_group_label>Placebo + Marijuana</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marijuana</intervention_name>
    <description>Smoked marijuana cigarette</description>
    <arm_group_label>Lorcaserin + Marijuana</arm_group_label>
    <arm_group_label>Placebo + Marijuana</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current cannabis use

          -  Able to give informed consent and perform study procedures

          -  Women practicing an effective form of birth control

          -  English speaking

        Exclusion Criteria:

          -  Presence of any clinically significant medical diagnoses

          -  History of heart disease and cardiac risk factors, severe chronic obstructive
             pulmonary disease, uncontrolled hypertension, or diabetes

          -  Current parole or probation

          -  Certain psychiatric diagnoses

          -  Current pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 14, 2017</study_first_submitted>
  <study_first_submitted_qc>August 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2017</study_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Margaret Haney</investigator_full_name>
    <investigator_title>Professor of Neurobiology (in Psychiatry) at CUMC</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

